Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.44 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.43 |
| ▸ | CCR1 | P32246 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | CCR8 | P51685 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | WNT3A | P56704 | 1/20 | 0.42 |
| ▸ | KDM5A | P29375 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | QDPR | P09417 | 1/20 | 0.39 |
| ▸ | SCN1A | P35498 | 1/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL827646 | 0.86 | CCR1 (0.52) | DRD4DRD2OPRM1OPRL1CCR1 | |
| Ammonia Solution, Strong SCHEMBL17820158 | 0.84 | CCR1 (0.50) | DRD4DRD2OPRM1OPRL1CCR1 | |
| SCHEMBL24681892 | 0.84 | DRD4 (0.45) | DRD4DRD2OPRM1OPRL1CXCR4 | |
| SCHEMBL27543939 | 0.84 | DRD4 (0.45) | DRD4DRD2OPRM1OPRL1CXCR4 | |
| SCHEMBL23331881 | 0.82 | CCR1 (0.48) | DRD4DRD2OPRM1OPRL1CCR1 | |
| SCHEMBL12093753 | 0.82 | CCR1 (0.48) | DRD4DRD2OPRM1OPRL1CXCR4 | |
| SCHEMBL13724434 | 0.82 | KDM5A (0.44) | WNT3AKDM5AMAP4K4LRRK2SYK | |
| SCHEMBL21037741 | 0.82 | DRD4 (0.48) | DRD4DRD2WNT3ASYKMAPK11 | |
| SCHEMBL21038285 | 0.82 | OPRM1 (0.42) | OPRM1OPRL1WNT3AMAPK11MAPK14 | |
| SCHEMBL29601235 | 0.82 | OPRM1 (0.42) | DRD4DRD2OPRM1OPRL1WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3750880-B1 | PYRAZINE-2(1H)-KETONE COMPOUND ACTING AS FGFR INHIBITOR | ZHANGZHOU PIEN TZE HUANG PHARM (CN) | 2022-12-21 | — | — | EP | disclosed |
| WO-2022236256-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| US-11286248-B2 | Pyrazine-2(1H)-ketone compound acting as FGFR inhibitor | ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) | 2022-03-29 | — | — | US | disclosed |
| US-20210040070-A1 | PYRAZINE-2(1H)-KETONE COMPOUND ACTING AS FGFR INHIBITOR | ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) | 2021-02-11 | — | — | US | disclosed |
| EP-3750880-A1 | PYRAZINE-2(1H)-KETONE COMPOUND ACTING AS FGFR INHIBITOR | Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd (CN) | 2020-12-16 | — | — | EP | disclosed |
| WO-2019154364-A1 | PYRAZINE-2(1H)-KETONE COMPOUND ACTING AS FGFR INHIBITOR | 南京明德新药研发有限公司 | 2019-08-15 | — | — | WO | disclosed |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20080119515-A1 | Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis | SCHERING CORPORATION | 2008-05-22 | — | — | US | disclosed |
| US-20080119515-A1 | Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis | SCHERING CORPORATION | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | DRD4 4544/4885DRD2 4124/4885OPRM1 1787/4885 |
| US-20210040070-A1 | PYRAZINE-2(1H)-KETONE COMPOUND ACTING AS FGFR INHIBITOR | FGFR1, FGFR2, FGFR3 | DRD4 4879/4885DRD2 4794/4885OPRM1 4314/4885 |
| US-20080119515-A1 | Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis | MAP3K20, MAP3K1, MAP3K19 | DRD4 4830/4885DRD2 4710/4885OPRM1 4221/4885 |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | DRD4 4544/4885DRD2 4124/4885OPRM1 1787/4885 |
| US-11286248-B2 | Pyrazine-2(1H)-ketone compound acting as FGFR inhibitor | FGFR1, FGFR2, FGFR3 | DRD4 4879/4885DRD2 4794/4885OPRM1 4314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.